Side-by-side comparison of AI visibility scores, market position, and capabilities
Uncommon Bio (formerly Higher Steaks) pivoted from cultivated pork to therapeutic biomanufacturing in 2024–2025; its cultivated meat platform was acquired by Meatable in 2025; now focuses on scalable cell biology tools for human health applications.
Uncommon Bio (formerly Higher Steaks) is a UK-based biotechnology company that underwent a significant strategic pivot in 2024–2025, transitioning from cultivated meat production toward developing scalable biomanufacturing technologies for human therapeutic applications. Founded by Benjamina Bollag, the company was originally focused on developing cultivated pork products using cell culture and bioprocess engineering techniques. In 2025, Uncommon Bio's cultivated meat platform and associated intellectual property were acquired by Meatable, a Netherlands-based cultivated meat company — allowing Uncommon Bio to exit the food application space and redirect its biomanufacturing expertise toward the healthcare and therapeutics sector.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.